Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3
Saved in:
Main Authors: | Ferreira,Emanuel, Oliveira,Nuno, Marques,Maria, Francisco,Luís, Santos,Ana, Carreira,Armando, Campos,Mário |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedad Española de Nefrología
2016
|
Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952016000100013 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
by: Ellithi,Moataz, et al.
Published: (2021) -
Eculizumab, a successful treatment for atypical postpartum hemolytic-uremic syndrome: a case report
by: Eznarriaga-Pérez,Isabel, et al.
Published: (2022) -
Subcapsular liver hematoma as a complication of an atypical hemolytic uremic syndrome
by: Ferreira,Emanuel, et al.
Published: (2015) -
Influenza B-Associated Atypical Hemolytic Uremic Syndrome
by: Mano,Lia, et al.
Published: (2022) -
Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome
by: Bello-Marquez,Diana Carolina, et al.
Published: (2021)